Gardiner Nathaniel S.

Avg. Two Year Performance

44% Avg. Purchase Return
20% Compound
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return3%12%16%(6%)44%
Purchase Success Rate1 of 21 of 21 of 21 of 21 of 2
Average Sale Return(6%)8%26%45%0%
Sale Success Rate0 of 11 of 11 of 11 of 10 of 1

Enanta Pharmaceuticals Inc

Drugs » Biotechnology

Chief Legal Officer:

Holdings: 111.61K shares

Sentiment

Insider Trading Sentiment: Accumulate

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--